Pruzanski named CEO of Alentis

Cancer and fibrosis company Alentis Therapeutics AG hired Mark Pruzanski, a physician entrepreneur who led his last two companies to takeouts. Pruzanski was CEO of Intercept Pharmaceuticals Inc., which he founded and led for nearly two decades, then chairman and CEO of obesity company Versanis Bio Inc. for a tenure made short by the obesity company’s 2023 acquisition by Eli Lilly and Co. (NYSE:LLY). He also chairs the boards of multiple biotechs and is a member of BIO’s board. Last fall, Alentis raised $181 million in a series D round led by OrbiMed Advisors, with Novo Holdings joining Jeito Capital as co-lead.

Veteran Korean biotech executive BG Rhee is joining Flagship Pioneering as a special adviser in South Korea and part of the firm’s push to expand into Asia. Rhee is chairman and CEO of Gi Innovation Inc. (KOSDAQ:358570) and chair of the International Vaccine Institute’s Korea Support Committee. Previously, he was CEO of Korean biotechs SCM Lifescience Co. Ltd. (KOSDAQ:298060) and Green Cross Corp. (KSE:006280), chairman of the Korea Biotechnology Industry Organization, and chairman of Korea’s Council for Advanced Regenerative Medicine...